EPISODE · Nov 30, 2025 · 44 MIN
S1, E14 - Orr Inbar, CEO Quant Health - AI Simulations of Clinical Trials
from Practical AI in Healthcare · host Steven Labkoff, MD and Leon Rozenblit, JD, PhD
Practical AI in Healthcare just released one of our most eye-opening conversations yet, featuring Orr Inbar, CEO & Co-Founder of QuantHealth.QuantHealth is pushing the boundaries of what’s possible in clinical development with AI-driven clinical trial simulation. Orr walked us through how modern deep learning, massive biological knowledge graphs, and patient-level real-world data can now simulate clinical trials with 80–90% accuracy — across dozens of indications, modalities, and trial phases.In our conversation, we cover:• How QuantHealth models patient-drug interactions at massive scale• Why trial design is still the most critical (and fixable) failure point in drug development• How simulation is becoming the new starting point for protocols• What AI-first trial design could mean for speed, cost, and reducing avoidable trial failures• Where the field is headed in the next 5–10 years — including the provocative question of how far simulation can replace human trialsOrr also discusses the acceleration of biological data, the maturity of real-world data, and transformer-based AI — the perfect storm that made this moment possible.This is one of the best deep dives yet into the practical future of drug development.
What this episode covers
Practical AI in Healthcare just released one of our most eye-opening conversations yet, featuring Orr Inbar, CEO & Co-Founder of QuantHealth.QuantHealth is pushing the boundaries of what’s possible in clinical development with AI-driven clinical trial simulation. Orr walked us through how modern deep learning, massive biological knowledge graphs, and patient-level real-world data can now simulate clinical trials with 80–90% accuracy — across dozens of indications, modalities, and trial phases.In our conversation, we cover:• How QuantHealth models patient-drug interactions at massive scale• Why trial design is still the most critical (and fixable) failure point in drug development• How simulation is becoming the new starting point for protocols• What AI-first trial design could mean for speed, cost, and reducing avoidable trial failures• Where the field is headed in the next 5–10 years — including the provocative question of how far simulation can replace human trialsOrr also discusses the acceleration of biological data, the maturity of real-world data, and transformer-based AI — the perfect storm that made this moment possible.This is one of the best deep dives yet into the practical future of drug development.
NOW PLAYING
S1, E14 - Orr Inbar, CEO Quant Health - AI Simulations of Clinical Trials
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.